Gilead Sciences, Inc. (GILD) Shares Bought by Brighton Jones LLC

Brighton Jones LLC lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,196 shares of the biopharmaceutical company’s stock after acquiring an additional 191 shares during the period. Brighton Jones LLC’s holdings in Gilead Sciences were worth $226,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also bought and sold shares of the company. Renaissance Group LLC raised its position in shares of Gilead Sciences by 3.0% in the 2nd quarter. Renaissance Group LLC now owns 378,020 shares of the biopharmaceutical company’s stock worth $26,756,000 after acquiring an additional 11,044 shares in the last quarter. CFO4Life Group LLC raised its position in shares of Gilead Sciences by 3.1% in the 2nd quarter. CFO4Life Group LLC now owns 10,429 shares of the biopharmaceutical company’s stock worth $738,000 after acquiring an additional 317 shares in the last quarter. Neuberger Berman Group LLC raised its position in shares of Gilead Sciences by 90.9% in the 2nd quarter. Neuberger Berman Group LLC now owns 2,583,196 shares of the biopharmaceutical company’s stock worth $182,839,000 after acquiring an additional 1,229,916 shares in the last quarter. Pacer Advisors Inc. raised its position in shares of Gilead Sciences by 69.9% in the 2nd quarter. Pacer Advisors Inc. now owns 77,085 shares of the biopharmaceutical company’s stock worth $5,456,000 after acquiring an additional 31,724 shares in the last quarter. Finally, BDO Wealth Advisors LLC bought a new position in shares of Gilead Sciences in the 2nd quarter worth about $1,010,000. 74.28% of the stock is owned by hedge funds and other institutional investors.

In related news, EVP James R. Meyers sold 60,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $83.19, for a total value of $4,991,400.00. Following the sale, the executive vice president now owns 62,715 shares in the company, valued at $5,217,260.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gregg H. Alton sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $79.00, for a total transaction of $3,950,000.00. Following the completion of the sale, the executive vice president now owns 113,237 shares in the company, valued at approximately $8,945,723. The disclosure for this sale can be found here. Insiders sold 358,486 shares of company stock worth $29,637,678 in the last 90 days. 1.30% of the stock is currently owned by corporate insiders.

Several research analysts have recently weighed in on the company. Mizuho set a $77.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research report on Sunday, October 29th. Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a research report on Friday, October 27th. BMO Capital Markets lowered their price objective on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a research report on Friday, October 27th. J P Morgan Chase & Co set a $85.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Finally, Leerink Swann lifted their price objective on Gilead Sciences from $84.00 to $85.00 and gave the stock a “market perform” rating in a research report on Thursday, October 19th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. Gilead Sciences has a consensus rating of “Buy” and an average price target of $85.68.

ILLEGAL ACTIVITY NOTICE: “Gilead Sciences, Inc. (GILD) Shares Bought by Brighton Jones LLC” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://www.com-unik.info/2017/11/03/gilead-sciences-inc-gild-shares-bought-by-brighton-jones-llc.html.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. During the same quarter last year, the company posted $2.75 earnings per share. The firm’s quarterly revenue was down 13.2% on a year-over-year basis.

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.82%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s dividend payout ratio is currently 23.69%.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

What are top analysts saying about Gilead Sciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gilead Sciences Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit